BCR and chronic myelogenous leukemia, BCR-ABL1 positive: This final analysis of the phase 1 study is the longest follow-up to date of asciminib monotherapy in patients with CML-CP without BCR::ABL1T315I with ≤ 8.4 years of therapy.